 |
PAC Med Biotech has achieved important milestones during its short history. Most notably, the PAC Med Biotech model of partnering with foreign companies for entry into India is now widely acclaimed and has emerged as a key reason for our success.
Our current project portfolio includes newly developed medicines (cardiology, obstetrics, dermatology), diagnostics (colon cancer, breast cancer, point-of-care kits), cosmetics (skin care), laboratory instruments and kits (nucleic acid extraction), and anti-counterfeit technologies for the pharmaceutical industry.
The following is a brief outline of our recent and current projects.
- introduced a cutting-edge, non-invasive colon cancer test developed in Europe that detects gene mutations in exfoliated cells contained in stool samples
- coordinated one of the largest clinical trials in the world for a breast cancer diagnostic test that is based on gene expression analysis of blood; structured the commercial entry of the test into India by recruiting a top pathlab chain for marketing
- introduced a leading obstetric drug developed in Europe after undertaking and obtaining product registration and all regulatory requirements for importation
- secured marketing rights for a novel cardiological drug, expected to be launched in India in early 2009
- introduced an award-winning technology for combating conterfeit drugs and ensuring secure supply chain tracking
- coordinating the entry of a best-in-class diagnostic test for rapid detection of chlamydia in males and females
- coordinating the entry of a vaginal pessary that delivers a labour-induction drug in a safe, sustained-release manner
- coordinating the entry of a novel line of skin care products that are based on an exfoliating enzyme obtained from marine sources
- coordinating the entry of a line of laboratory instruments and kits for efficient extraction of nucleic acids from difficult sources
|
 |
|
